WARNING: FETAL TOXICITY When pregnancy is detected, discontinue ENTRESTO as soon as possible (5.1) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus (5.1) WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue ENTRESTO as soon as possible. (5.1) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. (5.1)
Use: Labeled indications
- to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure.
- for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
Full indications and usage US FDA label
1 INDICATIONS AND USAGE ENTRESTO is a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal.
(1.1) for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. ENTRESTO reduces NT-proBNP and is expected to improve cardiovascular outcomes. (1.2) 1.1 Adult Heart Failure ENTRESTO is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure.
Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. LVEF is a variable measure, so use clinical judgment in deciding whom to treat [see Clinical Studies (14.1)]. 1.2 Pediatric Heart Failure ENTRESTO is indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
ENTRESTO reduces NT-proBNP and is expected to improve cardiovascular outcomes.
Contraindications
4 CONTRAINDICATIONS ENTRESTO is contraindicated: in patients with hypersensitivity to any component in patients with a history of angioedema related to previous ACE inhibitor or ARB therapy [see Warnings and Precautions (5.2)] with concomitant use of ACE inhibitors. Do not administer within 36 hours of switching from or to an ACE inhibitor [see Drug Interactions (7.1)] with concomitant use of aliskiren in patients with diabetes [see Drug Interactions (7.1)] Hypersensitivity to any component.
(4) History of angioedema related to previous ACEi or ARB therapy. (4) Concomitant use with ACE inhibitors. (4, 7.1) Concomitant use with aliskiren in patients with diabetes. (4, 7.1)
US FDA labelDosing: Adult
- The recommended starting dosage for adults is 49 mg/51 mg orally twice daily. The target maintenance dose is 97 mg/103mg orally twice daily. (2.2)
- Adjust adult doses every 2 to 4 weeks to the target maintenance dose, as tolerated by the patient. (2.2)
- For pediatric patients, see the Full Prescribing Information for recommended dosage, titrations, preparation and administration instructions. (2.3, 2.4, 2.5)
- Reduce starting dose to half the usually recommended starting dosage for: patients not currently taking an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) or previously taking a low dose of these agents. (2.6)
- patients with severe renal impairment. (2.7)
- patients with moderate hepatic impairment. (2.8)
2.1 General Considerations
2.1 General Considerations ENTRESTO is contraindicated with concomitant use of an angiotensin-converting enzyme (ACE) inhibitor. If switching from an ACE inhibitor to ENTRESTO allow a washout period of 36 hours between administration of the two drugs [see Contraindications (4) and Drug Interactions (7.1)].
2.2 Adult Heart Failure
2.2 Adult Heart Failure The recommended starting dose of ENTRESTO is 49/51 mg orally twice-daily. Double the dose of ENTRESTO after 2 to 4 weeks to the target maintenance dose of 97/103 mg twice daily, as tolerated by the patient.
2.3 Pediatric Heart Failure
2.3 Pediatric Heart Failure For the recommended dosage for pediatric patients aged 1 year and older, refer to Table 1 if using the tablets, or Table 2 if using the oral pellets. Take the recommended dose orally twice daily. Adjust pediatric patient doses every 2 weeks, as tolerated by the patient. Table 1: Recommended Dose and Titration for Pediatric Patients Using Tablets † Use of the oral suspension or oral pellets (see Table 2) is recommended in these patients.
Recommended mg/kg doses are of the combined amount of both sacubitril and valsartan [see Dosage and Administration (2.4, 2.5)]. ‡ Doses of 72 mg/78 mg can be achieved using three 24 mg/26 mg tablets [see Dosage Forms and Strengths (3)]. Titration Step Dose (twice daily) Weight (kg) Starting Second Final Less than 40 kg † 1.6 mg/kg 2.3 mg/kg 3.1 mg/kg At least 40 kg, less than 50 kg 24 mg/26 mg 49 mg/51 mg 72 mg/78 mg ‡ At least 50 kg 49 mg/51 mg 72 mg/78 mg ‡ 97 mg/103 mg Table 2: Recommended Dose and Titration for Pediatric Patients using ENTRESTO SPRINKLE † † When using capsules, more than one capsule may be needed to achieve recommended doses.
Oral pellets are contained within each capsule. Use the entire contents of the capsules to achieve the dose. ‡ Recommended mg/kg doses are of the combined amount of sacubitril and valsartan [see Dosage and administration (2.4)]. * For patients 50 kg or more, see Table 1. Titration Step Dose (twice daily) Weight (kg) * Starting Second Final Less than 13 (use oral suspension ‡) 1.6 mg/kg 2.3 mg/kg 3.1 mg/kg 13 to less than 19 12 mg/12 mg (Two 6 mg/6 mg capsules) 18 mg/18 mg (Three 6 mg/6 mg capsules) 24 mg/24 mg (Four 6 mg/6 mg capsules) 19 to less than 26 18 mg/18 mg (Three 6 mg/6 mg capsules) 24 mg/24 mg (Four 6 mg/6 mg capsules) 30 mg/32 mg (Two 15 mg/16 mg capsules) 26 to less than 34 24 mg/24 mg (Four 6 mg/6 mg capsules) 30 mg/32 mg (Two 15 mg/16 mg capsules) 45 mg/48 mg (Three 15 mg/16 mg capsules) 34 to less than 50 * 30 mg/32 mg (Two 15 mg/16 mg capsules) 45 mg/48 mg (Three 15 mg/16 mg capsules) 60 mg/64 mg (Four 15 mg/16 mg capsules)
2.4 Preparation of Oral Suspension Using Tablets
2.4 Preparation of Oral Suspension Using Tablets ENTRESTO oral suspension can be substituted at the recommended tablet dosage in patients unable to swallow tablets. ENTRESTO 800 mg/200 mL oral suspension can be prepared in a concentration of 4 mg/mL (sacubitril/valsartan 1.96/2.04 mg/mL). Use ENTRESTO 49/51 mg tablets in the preparation of the suspension.
To make an 800 mg/200 mL (4 mg/mL) oral suspension, transfer eight tablets of ENTRESTO 49/51 mg film-coated tablets into a mortar. Crush the tablets into a fine powder using a pestle. Add 60 mL of Ora-Plus ® into the mortar and triturate gently with pestle for 10 minutes, to form a uniform suspension. Add 140 mL of Ora-Sweet ® SF into mortar and triturate with pestle for another 10 minutes, to form a uniform suspension.
Transfer the entire contents from the mortar into a clean 200 mL amber colored PET or glass bottle. Place a press-in bottle adapter and close the bottle with a child resistant cap. The oral suspension can be stored for up to 15 days. Do not store above 25°C (77°F) and do not refrigerate. Shake before each use. * Ora-Sweet SF ® and Ora-Plus ® are registered trademarks of Paddock Laboratories, Inc.
2.5 Preparation and Administration of Oral Pellets
2.5 Preparation and Administration of Oral Pellets ENTRESTO SPRINKLE are oral pellets contained within capsules. Do not swallow the capsules. Do not chew or crush the oral pellets. ENTRESTO SPRINKLE can also be substituted in patients unable to swallow tablets. Use the entire contents of the capsules to achieve the dose. To administer ENTRESTO oral pellets, open the capsule and sprinkle the full content onto 1 to 2 teaspoons of soft food.
Consume the food containing the oral pellets immediately after adding them. Empty capsule shells must be discarded after use and not swallowed. Do not administer ENTRESTO oral pellets via nasogastric, gastrostomy, or other enteral tubes because it may cause obstruction of enteral tubes.
2.6 Dose Adjustment for Patients Not
2.6 Dose Adjustment for Patients Not Taking an ACE inhibitor or ARB or Previously Taking Low Doses of These Agents In patients not currently taking an ACE inhibitor or an angiotensin II receptor blocker (ARB) and for patients previously taking low doses of these agents, start ENTRESTO at half the usually recommended starting dose. After initiation, increase the dose every 2 to 4 weeks in adults and every 2 weeks in pediatric patients to follow the recommended dose escalation thereafter [see Dosage and Administration (2.2, 2.3)].
Note: Initiate pediatric patients weighing 40 to 50 kg who meet this criterion at 0.8 mg/kg twice daily using the oral suspension or oral pellets [see Dosage and Administration (2.3, 2.4, 2.5)].
2.7 Dose Adjustment for Severe Renal Impairment
2.7 Dose Adjustment for Severe Renal Impairment In adults and pediatric patients with severe renal impairment estimated glomerular filtration rate (eGFR less than 30 mL/min/1.73 m²), start ENTRESTO at half the usually recommended starting dose. After initiation, increase the dose to follow the recommended dose escalation thereafter [see Dosage and Administration (2.2, 2.3)].
Note: Initiate pediatric patients weighing 40 to 50 kg who meet this criterion at 0.8 mg/kg twice daily using the oral suspension or oral pellets [see Dosage and Administration (2.3, 2.4, 2.5)]. No starting dose adjustment is needed for mild or moderate renal impairment.
2.8 Dose Adjustment for Hepatic Impairment
2.8 Dose Adjustment for Hepatic Impairment In adults and pediatric patients with moderate hepatic impairment (Child-Pugh B classification), start ENTRESTO at half the usually recommended starting dose. After initiation, increase the dose to follow the recommended dose escalation thereafter [see Dosage and Administration (2.2, 2.3)].
Note: Initiate pediatric patients weighing 40 to 50 kg who meet this criterion at 0.8 mg/kg twice daily using the oral suspension or oral pellets [see Dosage and Administration (2.3, 2.4, 2.5)]. No starting dose adjustment is needed for mild hepatic impairment. Use in patients with severe hepatic impairment is not recommended.
Dosing: Altered kidney function
2.7 Dose Adjustment for Severe Renal Impairment In adults and pediatric patients with severe renal impairment estimated glomerular filtration rate (eGFR less than 30 mL/min/1.73 m²), start ENTRESTO at half the usually recommended starting dose. After initiation, increase the dose to follow the recommended dose escalation thereafter [see Dosage and Administration (2.2, 2.3)].
Note: Initiate pediatric patients weighing 40 to 50 kg who meet this criterion at 0.8 mg/kg twice daily using the oral suspension or oral pellets [see Dosage and Administration (2.3, 2.4, 2.5)]. No starting dose adjustment is needed for mild or moderate renal impairment.
8.7 Renal Impairment No dose adjustment is required in patients with mild (eGFR 60 to 90 mL/min/1.73 m²) to moderate (eGFR 30 to 60 mL/min/1.73 m²) renal impairment. Half of the starting dose is recommended in adult and pediatric patients with heart failure and with severe renal impairment (eGFR less than 30 mL/min/1.73 m²). [see Dosage and Administration (2.7), Warnings and Precautions (5.4) and Clinical Pharmacology (12.3)].
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Hepatic impairment
8.6 Hepatic Impairment No dose adjustment is required when administering ENTRESTO to patients with mild hepatic impairment (Child-Pugh A classification). Half of the starting dose is recommended in adult and pediatric patients with heart failure and with moderate hepatic impairment (Child-Pugh B classification). The use of ENTRESTO in patients with severe hepatic impairment (Child-Pugh C classification) is not recommended, as no studies have been conducted in these patients [see Dosage and Administration (2.8) and Clinical Pharmacology (12.3)].
2.8 Dose Adjustment for Hepatic Impairment In adults and pediatric patients with moderate hepatic impairment (Child-Pugh B classification), start ENTRESTO at half the usually recommended starting dose. After initiation, increase the dose to follow the recommended dose escalation thereafter [see Dosage and Administration (2.2, 2.3)].
Note: Initiate pediatric patients weighing 40 to 50 kg who meet this criterion at 0.8 mg/kg twice daily using the oral suspension or oral pellets [see Dosage and Administration (2.3, 2.4, 2.5)]. No starting dose adjustment is needed for mild hepatic impairment. Use in patients with severe hepatic impairment is not recommended.
US FDA labelDosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use The safety and effectiveness of ENTRESTO have been established for the treatment of heart failure in pediatric patients 1 year to less than 18 years. Use of ENTRESTO was evaluated in a multinational, randomized, double-blind trial comparing ENTRESTO and enalapril in 375 patients aged 1 month to less than 18 years (ENTRESTO n = 187; Enalapril n = 188) (PANORAMA-HF) [see Clinical Studies (14.2)].
The safety profile in pediatric patients (1 year to less than 18 years) receiving ENTRESTO was similar to that seen in adult patients. Limited safety and efficacy data in patients aged 1 month to less than 1 year were inadequate to support conclusions on safety and efficacy in this age group. Juvenile Animal Toxicity Data Sacubitril given orally to juvenile rats from postnatal day (PND) 7 to PND 35 or PND 70 (an age approximately equivalent to neonatal through pre-pubertal development or adulthood in humans) at doses greater than or equal to 400 mg/kg/day (approximately 2-fold the AUC exposure to the active metabolite of sacubitril, LBQ657, at an ENTRESTO pediatric clinical dose of 3.1 mg/kg twice daily) resulted in decreases in body weight, bone length, and bone mass.
The decrease in body weight was transient from PND 10 to PND 20 and the effects for most bone parameters were reversible after treatment stopped. Exposure at the No-Observed-Adverse-Effect-Level (NOAEL) of 100 mg/kg/day was approximately 0.5-fold the AUC exposure to LBQ657 at the 3.1 mg/kg twice daily dose of ENTRESTO. The mechanism underlying bone effects in rats and the translatability to pediatric patients are unknown.
Valsartan given orally to juvenile rats from PND 7 to PND 70 (an age approximately equivalent to neonatal through adulthood in humans) produced persistent, irreversible kidney damage at all dose levels. Exposure at the lowest tested dose of 1 mg/kg/day was approximately 0.2-fold the exposure at 3.1 mg/kg twice daily dose of ENTRESTO based on AUC.
These kidney effects in neonatal rats represent expected exaggerated pharmacological effects that are observed if rats are treated during the first 13 days of life. This period coincides with 36 weeks of gestation in humans, which could occasionally extend up to 44 weeks after conception in humans. In humans, nephrogenesis is thought to be complete around birth; however, maturation of other aspects of kidney function (such as glomerular filtration and tubular function) may continue until approximately 2 years of age.
It is unknown whether post-natal use of valsartan before maturation of renal function is complete has long-term deleterious effects on the kidney.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use There were 4,143 and 3,971 heart failure patients 65 years of age and older in PARADIGM-HF and PARAGON-HF, respectively [see Clinical Studies (14)]. Of the total number of ENTRESTO-treated patients, 2,087 (49.6%) and 1,995 (82.9%) were 65 years of age and older, while 786 (18.7%) and 1,100 (45.7%) were 75 years of age and older in PARADIGM-HF and PARAGON-HF, respectively.
No overall differences in safety or effectiveness of ENTRESTO have been observed between patients 65 years of age and older and younger adult patients in either study. No relevant pharmacokinetic differences have been observed in elderly (≥ 65 years) or very elderly (≥ 75 years) patients compared to the overall population [see Clinical Pharmacology (12.3)].
Administration
2.4 Preparation of Oral Suspension Using Tablets ENTRESTO oral suspension can be substituted at the recommended tablet dosage in patients unable to swallow tablets. ENTRESTO 800 mg/200 mL oral suspension can be prepared in a concentration of 4 mg/mL (sacubitril/valsartan 1.96/2.04 mg/mL). Use ENTRESTO 49/51 mg tablets in the preparation of the suspension. To make an 800 mg/200 mL (4 mg/mL) oral suspension, transfer eight tablets of ENTRESTO 49/51 mg film-coated tablets into a mortar. Crush the tablets into a fine powder using a pestle. Add 60 mL of Ora-Plus ® into the mortar and triturate gently with pestle for 10 minutes, to form a uniform suspension. Add 140 mL of Ora-Sweet ® SF into mortar and triturate with pestle for another 10 minutes, to form a uniform suspension. Transfer the entire contents from the mortar into a clean 200 mL amber colored PET or glass bottle. Place a press-in bottle adapter and close the bottle with a child resistant cap. The oral suspension can be stored for up to 15 days. Do not store above 25°C (77°F) and do not refrigerate. Shake before each use. * Ora-Sweet SF ® and Ora-Plus ® are registered trademarks of Paddock Laboratories, Inc.
2.5 Preparation and Administration of Oral Pellets ENTRESTO SPRINKLE are oral pellets contained within capsules. Do not swallow the capsules. Do not chew or crush the oral pellets. ENTRESTO SPRINKLE can also be substituted in patients unable to swallow tablets. Use the entire contents of the capsules to achieve the dose. To administer ENTRESTO oral pellets, open the capsule and sprinkle the full content onto 1 to 2 teaspoons of soft food. Consume the food containing the oral pellets immediately after adding them. Empty capsule shells must be discarded after use and not swallowed. Do not administer ENTRESTO oral pellets via nasogastric, gastrostomy, or other enteral tubes because it may cause obstruction of enteral tubes.
US FDA labelDosage forms
Philippines
- Sodium salt complex): 50 mg Film-Coated Tablet (eq. to Sacubitril 24.3 mg + Valsartan 25.7 mg, 100 mg Film-Coated Tablet (eq. to Sacubitril 48.6 mg + Valsartan 51.4 mg, 200 mg Film-Coated Tablet (eq. to Sacubitril + 97.2 mg + Valsartan 102.8 mg, 200 mg Film-Coated Tablet (eq. to Sacubitril 97.2 mg + Valsartan 102.8 mg
- ) film-coated tablet: 50 mg (eq. to Sacubitril 24 mg + Valsartan 26 mg, 50 mg (eq. to Sacubitril 24.3 mg + Valsartan 25.7 mg, 50 mg (equivalent to Sacubitril 24 mg + Valsartan 26 mg, 100 mg (46.6 mg/51.4 mg, 100 mg (eq. to Sacubitril 48.6 mg + Valsartan 51.4 mg, 100 mg (eq. to Sacubitril 49 mg + Valsartan 51 mg, 100 mg (equivalent to Sacubitril 49 mg + Valsartan 51 mg, 200 mg (97.2 mg/102.8 mg, 200 mg (eq. to Sacubitril 97 mg + Valsartan 103 mg, 200 mg (eq. to Sacubitril 97.2 mg + Valsartan 102.8 mg, …
- Valsartan sodium salt complex) film-coated tablet: 50 mg (equivalent to 24 mg Sacubitril + 26 mg, 100 mg (eq. to 48.6 mg Sacubitril + 51.4 mg, 100 mg (equivalent to 48.6 mg Sacubitril and 51.4 mg, 100 mg(eq. to 48.6 mg sacubitril + 51.4 mg, 200 mg (eq. to 97.2 mg sacubitril + 102.8 mg, 200 mg (equivalent to 97.2 mg sacubitril + 102.8 mg
- Sodium salt complex) film-coated tablet: 50 mg (eq. to Sacubitril 24.3 mg + Valsartan 25.7 mg, 50 mg Film-Coated Tablet (eq. to Sacubitril 24.3 mg + Valsartan 25.7 mg, 100 mg (eq. to Sacubitril 48.6 mg + Valsartan 51.4 mg, 100 mg Film-Coated Tablet (eq. to Sacubitril 48 .6 mg + Valsartan 51.4 mg, 200 mg (eq. to Sacubitril 97.2 mg + Valsartan 102.8 mg
- Tablet: 50 mg, 100 mg, 200 mg
- ): 50 mg 50 mg Film-Coated Tablet (eq. to Sacubitril 24.3 mg + Valsartan 25.7 mg, 100 mg Film Coated Tablet (eq. to Sacubitril 48.6 mg + Valsartan 51.4 mg
- Film-coated tablet: 50 mg, 100 mg
- In sodium salt complex) film-coated tablet: 50 mg to (eq Sacubitril 24 mg + Valsartan 26 mg, 100 mg (eq. to Sacubitril 49 mg + Valsartan 51 mg
- Valsartan as crystalline sodium salt complex): 100 mg Film-Coated Tablet (eq. to 48.6 mg sacubitril and 51.4 mg, 200 mg Film-Coated Tablet (eq. to 97.2 mg sacubitril and 102.8 mg
- Valsartan): 50 mg Film-Coated Tablet (eq. to 24.3 mg Sacubitril + 25.7 mg, 200 mg Film-Coated Tablet (eq. to 97.2 mg Sacubitril + 102.8 mg
and 6 more forms; see the products table.
Registered products in the Philippines
103 products registered with the Food and Drug Administration (FDA) Philippines list Sacubitril + Valsartan as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products103
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
Acusart 50Sacubitril + Valsartan | 50 mg Film-Coated Tablet (eq. to Sacubitril 24.3 mg + Valsartan 25.7 mg Sodium Salt Complex)Alu/Alu Blister Pack x 10's Box of 30's | Rx | Exemed PharmaceuticalsIndia | Emcure Pharma Philippines Inc.Importer: AMB HK Enterprises Inc. | DRP-16476-01 | Mar 25, 2030 | |
Arnimax 100Sacubitril + Valsartan | 100 mg Film-Coated Tablet (eq. to Sacubitril 48.6 mg + Valsartan 51.4 mg sodium salt complex)Alu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Exemed PharmaceuticalsIndia | JustRight Healthcare Inc.Importer: AMB HK Enterprises Inc. | DRP-16447-08 | Mar 18, 2030 | |
Arnimax 200Sacubitril + Valsartan | 200 mg Film-Coated Tablet (eq. to Sacubitril + 97.2 mg + Valsartan 102.8 mg sodium salt complex)Alu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Exemed PharmaceuticalsIndia | JustRight Healthcare Inc.Importer: AMB HK Enterprises Inc. | DRP-16446-07 | Mar 18, 2030 | |
Arnimax 50Sacubitril + Valsartan | 50 mg Film-Coated Tablet (eq. to Sacubitril 24.3 mg + Valsartan 25.7 mg sodium salt complex)Alu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Exemed PharmaceuticalsIndia | JustRight Healthcare Inc.Importer: AMB HK Enterprises Inc. | DRP-16448-06 | Mar 18, 2030 | |
Cardiduo 200Sacubitril + Valsartan | 200 mg (eq. to Sacubitril 97.2 mg + Valsartan 102.8 mg) Film-Coated Tablet | Rx | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DR-XY49631 | Feb 10, 2031 | |
Cardiduo 50Sacubitril + Valsartan | 50 mg (eq. to Sacubitril 24.3 mg + Valsartan 25.7 mg) Film-Coated Tablet | Rx | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DR-XY49633 | Feb 10, 2031 | |
CubizartSacubitril + Valsartan | 200 mg Film-Coated Tablet (eq. to Sacubitril 97.2 mg + Valsartan 102.8 mg sodium salt complex)Alu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Exemed PharmaceuticalsIndia | Lakeside Pharmaceuticals Phil., Inc.Importer: AMB HK Enterprises Inc. | DRP-16446-08 | Mar 18, 2030 | |
CUBIZARTSacubitril + Valsartan | 50 mg Film-Coated Tablet (eq. to Sacubitril 24.3 mg + Valsartan 25.7 mg sodium salt complex)Alu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Exemed PharmaceuticalsIndia | Lakeside Pharmaceuticals Phil., Inc.Importer: AMB HK Enterprises Inc. | DRP-16448-09 | Mar 18, 2030 | |
Duovasc 100Sacubitril + Valsartan | 100 mg (eq. to Sacubitril 49 mg + Valsartan 51 mg) Film-Coated TabletAlu/Alu Blister Pack of 10's (Box of 30's and 100's) | Rx | Ratnatris Pharmaceuticals Private LimitedIndia | Medinova Pharmaceutical Inc. | DRP-17586 | Feb 5, 2031 | |
Duovasc 200Sacubitril + Valsartan | 200 mg (eq. to Sacubitril 97 mg + Valsartan 103 mg) Film-Coated TabletAlu/Alu Blister Pack of 10's (Box of 30's and 100's) | Rx | Ratnatris Pharmaceuticals Private LimitedIndia | Medinova Pharmaceutical Inc. | DRP-17585 | Feb 5, 2031 | |
Duovasc 50Sacubitril + Valsartan | 50 mg (eq. to Sacubitril 24 mg + Valsartan 26 mg) Film- Coated TabletAlu/Alu Blister Pack of 10's (Box of 30's and 100's) | Rx | Ratnatris Pharmaceuticals Private LimitedIndia | Medinova Pharmaceutical Inc. | DRP-17587 | Feb 5, 2031 | |
EntrestoSacubitril-Valsartan | 100 mg Film-Coated Tablet (eq. to 48.6 mg sacubitril and 51.4 mg valsartan as crystalline sodium salt complex)PA / AL / PVC (Alu-Alu) Blister Pack x 14's (Box of 2 blister packs x 14 tablets) | Rx | Novartis Farma S.p.A.Italy | Importer: Novartis Healthcare Philippines, Inc. | DRP-16333 | Jul 20, 2028 | |
EntrestoSacubitril + Valsartan | 100 mg Film-Coated Tablet (eq. to 48.6 mg sacubitril and 51.4 mg valsartan as crystalline sodium salt complex) TabletPA/AL/PVC (Alu-Alu) Blister Pack x 14’s (Box of 2 blister packs x 14 tablets) | Rx | Novartis Farma S.p.A.Singapore | Importer: Novartis Healthcare Philippines, Inc. | DR-XY45113 | Jul 20, 2028 | |
EntrestoSacubitril-Valsartan | 200 mg Film-Coated Tablet (eq. to 97.2 mg sacubitril and 102.8 mg valsartan as crystalline sodium salt complex)PA /AL / PVC (Alu-Alu) Blister Pack x 7's (Box of 8 blister packs x 7 tablets) | Rx | Novartis Farma S.p.A.Italy | Importer: Novartis Healthcare Philippines, Inc. | DRP-16331 | Jul 20, 2028 | |
EntrestoSacubitril + Valsartan | 200 mg Film-Coated Tablet (eq. to 97.2 mg sacubitril and 102.8 mg valsartan as crystalline sodium salt complex) Film-Coated TabletPA/AL/PVC (Alu-Alu) Blister Pack x 14’s (Box of 2 blister packs x 14 tablets) | Rx | Novartis Farma S.p.A.Singapore | Importer: Novartis Healthcare Philippines, Inc. | DR-XY45114 | Jul 20, 2028 | |
EntrestoSacubitril + Valsartan | 50 mg (eq. Sacubitril 24.3 mg + Valsartan 25.7 mg sodium salt complex) TabletPA/AL/PVC (Alu-Alu) Blister Pack x 14's (Box of 2 blister packs x 14 tablets) | Rx | Novartis Singapore Pharmaceutical Manufacturing Pte. LtdSingapore | Importer: Novartis Healthcare Philippines, Inc. | DR-XY45112 | Jul 20, 2028 | |
EntrestoSacubitril-Valsartan | 50 mg Film-Coated Tablet (eq. to 24.3 mg sacubitril and 25.7 mg valsartan as crystalline sodium salt complexPA / AL/ PVC (Alu-Alu) Blister Pack x 14's (Box of 2 blister packs x 14 tablets) | Rx | Novartis Farma S.p.A.Italy | Importer: Novartis Healthcare Philippines, Inc. | DRP-16332 | Jul 20, 2028 | |
NoneSacubitril + Valsartan | 100mg (eq. to 48.6 mg Sacubitril + 51.4 mg Valsartan sodium salt complex) Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Bafna Pharmaceuticals LimitedIndia | I.E. Medica, Inc.Importer: Medethix, Inc. | DPR-17289-01 | Nov 17, 2030 | |
NoneSacubitril + Valsartan | 200 mg Film-Coated Tablet (eq. to Sacubitril 97.2 mg + Valsartan 102.8 mg sodium salt complex)Alu/Alu Blister Pack x 10's (Box of 30’s) | Rx | Avantika Medex Private LimitedIndia | Ambitech Biopharmaceuticals Inc.Importer: Nelpa Lifesciences, Inc. | DRP-17567-03 | Jan 27, 2031 | |
NoneSacubitril + Valsartan | 200 mg Film-Coated Tablet (eq. to Sacubitril 97.2 mg + Valsartan 102.8 mg sodium salt complex)Alu/Alu Blister Pack x 10’s (Box of 30's) | Rx | Avantika Medex Private LimitedIndia | Ambitech Biopharmaceuticals Inc.Importer: Nelpa Lifesciences, Inc. | DRP-17567-05 | Jun 27, 2031 | |
NoneSacubitril + Valsartan | 50 mg (equivalent to 24 mg Sacubitril + 26 mg Valsartan sodium salt complex) Film-coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Bafna Pharmaceuticals LimitedIndia | I.E. Medica, Inc.Importer: Medethix, Inc. | DRP-17288-02 | Nov 17, 2030 | |
NoneSacubitril + Valsartan | 50 mg Film-Coated Tablet (eq. to Sacubitril 24.3 mg + Valsartan 25.7 mg sodium salt complex)Alu/Alu Blister Pack x 10's (Box of 30's) | Rx | Avantika Medex Private LimitedIndia | Actimed, Inc.Importer: Nelpa Lifesciences, Inc. | DRP-17569-03 | Jan 27, 2031 | |
NoneSacubitril + Valsartan | 50 mg Film-Coated Tablet (eq. to Sacubitril 24.3 mg + Valsartan 25.7 mg sodium salt complex)Alu/Alu Blister Pack x 10's (Box of 30’s) | Rx | Avantika Medex Private LimitedIndia | Ambitech Biopharmaceuticals Inc.Importer: Nelpa Lifesciences, Inc. | DRP-17569-04 | Jan 21, 2031 | |
Omsaval 100Sacubitril + Valsartan | 100 mg (eq. to Sacubitril 49 mg + Valsartan 51 mg) Film-Coated Tablet | Rx | Ratnatris Pharmaceuticals Pvt. Ltd.India | Ambica International Corporation | DRP-17714 | Feb 20, 2031 | |
Omsaval 200Sacubitril + Valsartan | 200 mg (eq. to Sacubitril 97 mg + Valsartan 103 mg) Film-Coated Tablet | Rx | Ratnatris Pharmaceuticals Pvt. Ltd.India | Ambica International Corporation | DRP-17713 | Feb 20, 2031 | |
Omsaval 50Sacubitril + Valsartan | 50 mg (eq. to Sacubitril 24 mg + Valsartan 26 mg) Film- Coated Tablet | Rx | Ratnatris Pharmaceuticals Pvt. Ltd.India | Ambica International Corporation | DRP-17715 | Feb 20, 2031 | |
PavioSacubitril + Valsartan | 100mg Film-Coated Tablet (eq. to Sacubitril 48.6 mg + Valsartan 51.4 mg sodium salt complex)Alu/Alu Blister Pack x 10's (Box of 30’s) | Rx | Avantika Medex Private LimitedIndia | Pharma Hub CorporationImporter: Nelpa Lifesciences Inc. | DRP-17568-01 | Jan 27, 2031 | |
PavioSacubitril + Valsartan | 50mg Film-Coated Tablet (eq. to Sacubitril 24.3 mg + Valsartan 25.7 mg sodium salt complex)Alu/Alu Blister Pack x 10's (Box of 30’s) | Rx | Avantika Medex Private LimitedIndia | Pharma Hub CorporationImporter: Nelpa Lifesciences Inc. | DRP-17569-01 | Jan 27, 2031 | |
SACTRILSACUBITRIL + VALSARTAN | 100mg (eq. to 48.6mg Sacubitril + 51.4mg Valsartan sodium salt complex) Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Bafna Pharmaceuticals LimitedIndia | Natrapharm Inc.Importer: Medethix, Inc. | DRP-17289-03 | Nov 17, 2030 | |
SACTRILSacubitril + Valsartan | 200 mg (eq. to 97.2mg Sacubitril + 102.8mg Valsartan sodium salt complex) Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Bafna Pharmaceutical LimitedIndia | Natrapharm Inc.Importer: Medethix, Inc. | DRP-17290-03 | Nov 17, 2030 | |
SactrilSacubitril + Valsartan | 50mg (equivalent to 24mg Sacubitril + 26mg Valsartan sodium salt complex) Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Bafna Pharmaceuticals LimitedIndia | Natrapharm, Inc.Importer: Medethix, Inc. | DRP-17288-01 | Nov 17, 2030 | |
Sacultra PlusSacubitril + Valsartan | 100 mg Film-Coated Tablet (eq. to Sacubitril 48.6 mg + Valsartan 51.4 mg sodium salt complex)Alu/Alu Blister Pack x 10's (Box of 30’s) | Rx | Avantika Medex Private LimitedIndia | Ultramed Pharma, Inc.Importer: Nelpa Lifesciences, Inc. | DRP-17568-05 | Jan 27, 2031 | |
Sacultra PlusSacubitril + Valsartan | 200 mg Film-Coated Tablet (eq. to Sacubitril 97.2 mg + Valsartan 102.8 mg sodium salt complex)Alu/Alu Blister Pack x 10's (Box of 30’s) | Rx | Avantika Medex Private LimitedIndia | Ultramed Pharma, Inc.Importer: Nelpa Lifesciences, Inc. | DRP-17567-02 | Jan 27, 2031 | |
Sacuvex 100Sacubitril + Valsartan | 100 mg (eq. to Sacubitril 49 mg + Valsartan 51 mg) Film-Coated TabletAlu/Alu Blister Pack of 10's (Box of 30's and 100's) | Rx | Ratnatris Pharmaceuticals Private LimitedIndia | GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc. | DRP-17586-01 | Feb 5, 2031 | |
Sacuvex 200Sacubitril + Valsartan | 200 mg (eq. to Sacubitril 97 mg + Valsartan 103 mg) Film-Coated TabletAlu/Alu Blister Pack of 10's (Box of 30's and 100's) | Rx | Ratnatris Pharmaceuticals Private LimitedIndia | GA2 Pharmaceutical Inc.Importer: Medinova Pharmaceutical Inc. | DRP-17585-01 | Feb 5, 2031 | |
Sacuvex 50Sacubitril + Valsartan | 50 mg (eq. to Sacubitril 24 mg + Valsartan 26 mg) Film-Coated TabletAlu/Alu Blister Pack of 10's (Box of 30's and 100's) | Rx | Ratnatris Pharmaceuticals Private LimitedIndia | GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc. | DRP-17587-01 | Feb 5, 2031 | |
SanareSacubitril + Valsartan | 100 mg Film-Coated Tablet (eq. to Sacubitril 48.6 mg + Valsartan 51.4 mg sodium salt complex)Alu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Exemed PharmaceuticalsIndia | Corbridge Group Phils., Inc.Importer: Amb HK Enterprises Inc. | DRP-16447-02 | Mar 18, 2030 | |
SanareSacubitril + Valsartan | 200 mg Film-Coated Tablet (eq. to Sacubitril 97.2 mg + Valsartan 102.8 mg sodium salt complex)Alu/Alu Blister Pack x 10's (Box of 30's) | Rx | Exemed PharmaceuticalsIndia | Corbridge Group Phils., Inc.Importer: AMB HK Enterprises Inc. | DRP-16446-02 | Mar 18, 2030 | |
SanareSacubitril + Valsartan | 50 mg Film-Coated Tablet (eq. to Sacubitril 24.3 mg + Valsartan 25.7 mg sodium salt complex)Alu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Exemed PharmaceuticalsIndia | Corbridge Group Phils., Inc.Importer: Amb Hk Enterprises Inc. | DRP-16448-02 | Mar 18, 2030 | |
SartrestanSacubitril + Valsartan | 50 mg Film-Coated Tablet (eq. to Sacubitril 24.3 mg + Valsartan 25.7 mg sodium salt complex)Alu/Alu Blister Pack x 7's (Box of 14’s); Alu/Alu Blister Pack x 10's (Box of 30’s) | Rx | Avantika Medex Private LimitedIndia | Asterzenmed Inc.Importer: Nelpa Lifesciences, Inc. | DRP-17569-02 | Jan 27, 2031 | |
Savator 100.Sacubitril + Valsartan | 100 mg TabletAlu-Alu Blister Pack x 10's (Box of 1 blister pack x 10 tablets; Box of 3 blister pack x 10 tablets; Box of 10 blister packs x 10 tablets) | Rx | Torrent Pharmaceuticals Ltd.India | Torrent Pharma Philippines, Inc. | DR-XY49350 | Mar 5, 2029 | |
Savator 200Sacubitril + Valsartan | 200 mg TabletAlu-alu Blister Pack x 10's (Box of 1 blister pack x 10 tablets; Box of 3 blister pack x 10 tablets; Box of 10 blister pack x 10 tablets) | Rx | Torrent Pharmaceuticals Ltd.India | Torrent Pharma Philippines, Inc. | DR-XY49348 | Mar 5, 2030 | |
Savator 50Sacubitril + Valsartan | 50 mg TabletAlu-Alu Blister Pack x 10's (Box of 1 blister pack x 10 tablets; Box of 3 blister pack x 10 tablets; Box of 10 blister packs x 10 tablets) | Rx | Torrent Pharmaceuticals Ltd.India | Torrent Pharma Philippines, Inc. | DR-XY49349 | Mar 5, 2030 | |
SolevaltrilSacubitril + Valsartan | 100 mg Film-Coated Tablet (eq. to Sacubitril 48.6 mg + Valsartan 51.4 mg sodium salt complex)Alu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Exemed PharmaceuticalsIndia | Sun Pharma Philippines, Inc.Importer: AMB HK Enterprises Inc. | DRP-16447-07 | Mar 18, 2030 | |
SolevaltrilSacubitril + Valsartan | 50 mg Film-Coated Tablet (eq. to Sacubitril 24.3 mg + Valsartan 25.7 mg sodium salt complex)Alu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Exemed PharmaceuticalsIndia | Sun Pharma Philippines, Inc.Importer: AMB HK Enterprises Inc. | DRP-16448-07 | Mar 18, 2030 | |
TorvatrilSacubitril + Valsartan | 100 mg Film-Coated Tablet (eq. to Sacubitril 48.6 mg + Valsartan 51.4 mg sodium salt complex)Alu/Alu Blister Pack x 7's (Box of 14's); Alu/Alu Blister Pack x 10's (Box of 30's) | Rx | Avantika Medex Private LimitedIndia | Ambitech Biopharmaceuticals Inc.Importer: Nelpa Lifesciences, Inc. | DRP-17568-03 | Jan 27, 2031 | |
TorvatrilSacubitril + Valsartan | 50 mg Film-Coated Tablet (eq. to Sacubitril 24.3 mg + Valsartan 25.7 mg sodium salt complex)Alu/Alu Blister Pack x 7's (Box of 14's); Alu/Alu Blister Pack x 10's (Box of 30's) | Rx | Avantika Medex Private LimitedIndia | Ambitech Biopharmaceuticals Inc.Importer: Nelpa Lifesciences, Inc. | DRP-17569-05 | Jan 27, 2031 | |
Trivasaph-100Sacubitril + Valsartan | 100 mg (46.6 mg/51.4 mg) Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Sai Parenterals Ltd.India | Nelpa Lifesciences, Inc. | DRP-18982 | Oct 13, 2031 | |
Trivasaph-200Sacubitril + Valsartan | 200 mg (97.2mg/102.8mg) Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s and 100’s) | Rx | Sai Parenterals Ltd.India | Nelpa Lifesciences, Inc. | DRP-18642 | Aug 11, 2031 | |
Trivasaph-50Sacubitril + Valsartan | 50 mg Film-Coated Tablet (eq. to Sacubitril 24.3 mg + Valsartan 25.7 mg sodium salt complex)Alu/Alu Blister Pack x 10’s (Box of 30’s and 100’s) | Rx | Sai Parenterals Ltd.India | Nelpa Lifesciences, Inc. | DRP-18643 | Aug 11, 2031 | |
Trivasaph-A100Sacubitril + Valsartan | 100 mg (eq. to Sacubitril 48.6 mg + Valsartan 51.4 mg sodium salt complex) Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 14's); Alu/Alu Blister Pack x 10's (Box of 30's) | Rx | Avantika Medex Private LimitedIndia | Nelpa Lifesciences, Inc. | DRP-17568 | Jan 27, 2031 | |
Trivasaph-A200Sacubitril + Valsartan | 200 mg (eq. to Sacubitril 97.2 mg + Valsartan 102.8 mg sodium salt complex) Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 14's); Alu/Alu Blister Pack x 10's (Box of 30's) | Rx | Avantika Medex Private LimitedIndia | Nelpa Lifesciences, Inc. | DRP-17567 | Jan 27, 2031 | |
Trivasaph-A50Sacubitril + Valsartan | 50 mg (eq. to Sacubitril 24.3 mg + Valsartan 25.7 mg sodium salt complex) Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 14's); Alu/Alu Blister Pack x 10's (Box of 30's) | Rx | Avantika Medex Private LimitedIndia | Nelpa Lifesciences, Inc. | DRP-17569 | Jan 27, 2031 | |
UnbrandedSacubitril + Valsartan | 200 mg (equivalent to 97.2 mg sacubitril + 102.8 mg valsartan sodium salt complex) Film-coated TabletAlu/Alu Blister pack x 10's (Box of 30's) | Rx | Bafna Pharmaceuticals LimitedIndia | I.E. Medica, Inc.Importer: Medethix, Inc. | DRP-17290-02 | Nov 17, 2030 | |
ValcubitSacubitril + Valsartan (sodium hemipentahydrate) | 100 mg (eq. to Sacubitril 49 mg + Valsartan 51 mg) Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Base Medico Private LimitedIndia | AMB HK Enterprises Inc. | DRP-18061 | Apr 30, 2031 | |
ValcubitSacubitril + Valsartan (sodium hemipentahydrate) | 200 mg (eq. to Sacubitril 97 mg + Valsartan 103 mg) Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Base Medico Private LimitedIndia | AMB HK Enterprises Inc. | DRP-18060 | Apr 30, 2031 | |
ValcubitSacubitril + Valsartan (sodium hemipentahydrate) | 50 mg (eq. to Sacubitril 24 mg + Valsartan 26 mg) Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Base Medico Private LimitedIndia | AMB HK Enterprises Inc. | DRP-18062 | Apr 30, 2031 | |
Valcubit-100Sacubitril + Valsartan | 100 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Exemed PharmaceuticalsIndia | AMB HK Enterprises Inc | DRP-16447 | Mar 18, 2030 | |
Valcubit-200Sacubitril + Valsartan | 200 mg (eq. to Sacubitril 97.2 mg + Valsartan 102.8 Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's) | Rx | Globela Pharma Private LimitedIndia | AMB HK Enterprises Inc. | DRP-16446 | Mar 18, 2030 | |
Valcubit-50Sacubitril + Valsartan | 50 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Exemed PharmaceuticalsIndia | AMB HK Enterprises IncImporter: AMB HK Enterprises Inc. | DRP-16448 | Mar 18, 2030 | |
Valsac-100Sacubitril + Valsartan | 100 mg Film Coated Tablet (eq. to Sacubitril 48.6 mg + Valsartan 51.4 mg)Alu/Alu Blister Pack x 10's (Box of 30's) | Rx | Exemed PharmaceuticalsIndia | AMB HK Enterprises IncImporter: AMB HK Enterprises Inc. | DRP-16475 | Mar 25, 2030 | |
Valsac-50Sacubitril + Valsartan | 50 mg 50 mg Film-Coated Tablet (eq. to Sacubitril 24.3 mg + Valsartan 25.7 mg)Alu/Alu Blister Pack x 10's (Box of 30's) | Rx | Exemed PharmaceuticalsIndia | AMB HK Enterprises IncImporter: AMB HK Enterprises Inc. | DRP-16476 | Mar 25, 2030 | |
ValsanthixSacubitril + Valsartan | 100 mg (eq. to 48.6 mg Sacubitril + 51.4 mg Valsartan sodium salt complex) Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Bafna Pharmaceuticals LimitedIndia | Medethix, Inc. | DRP-17289 | Nov 17, 2030 | |
ValsanthixSacubitril + Valsartan | 200 mg (eq. to 97.2 mg Sacubitril + 102.8 mg Valsartan sodium salt complex) Film-coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Bafna Pharmaceuticals LimitedIndia | Medethix, Inc. | DRP-17290 | Nov 17, 2030 | |
ValsanthixSacubitril + Valsartan | 50 mg (equivalent to 24 mg Sacubitril + 26 mg Valsartan sodium salt complex) Film-coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Bafna Pharmaceuticals LimitedIndia | Medethix, Inc. | DRP-17288 | Nov 17, 2030 | |
ValsatrilSacubitril + Valsartan | 100 mg Film-Coated Tablet (eq. to Sacubitril 48 .6 mg + Valsartan 51.4 mg sodium salt complex) Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Exemed PharmaceuticalsIndia | Ajanta Pharma Philippines, Inc.Importer: AMB HK Enterprises Inc. | DRP-16447-09 | Mar 18, 2030 | |
ValsatrilSacubitril + Valsartan | 200 mg Film-Coated Tablet (eq. to Sacubitril 97.2 mg + Valsartan 102.8 mg sodium salt complex)Alu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Exemed PharmaceuticalsIndia | Ajanta Pharma Philippines, Inc.Importer: AMB HK Enterprises Inc. | DRP-16446-04 | Mar 18, 2030 | |
VALSATRILSacubitril + Valsartan | 50 mg Film-Coated Tablet (eq. to Sacubitril 24.3 mg + Valsartan 25.7 mg sodium salt complex) Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Exemed PharmaceuticalsIndia | Ajanta Pharma Philippines, Inc.Importer: AMB HK Enterprises Inc. | DRP-16448-08 | Mar 18, 2030 | |
ValsatrixSacubitril + Valsartan | 100 mg Film-Coated Tablet (eq. to Sacubitril 48.6 mg + Valsartan 51.4 mg sodium salt complex)Alu / Alu Blister Pack x 10's (Box of 30's) | Rx | Exemed PharmaceuticalsIndia | PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-16447-03 | Mar 18, 2030 | |
VALSATRIXSacubitril + Valsartan | 200 mg (eq. to Sacubitril 97.2 mg + Valsartan 102.8 mg sodium salt complex) Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Exemed PharmaceuticalsIndia | PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-16446-05 | Mar 18, 2030 | |
ValsatrixSacubitril + Valsartan | 50 mg (eq. to Sacubitril 24.3 mg + Valsartan 25.7 mg sodium salt complex) Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Exemed PharmaceuticalsIndia | PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-16448-03 | Mar 18, 2030 | |
ValsitrilSacubitril + Valsartan | 100 mg (eq. to 48.6 mg Sacubitril + 51.4 mg Valsartan sodium salt complex) Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Bafna Pharmaceuticals LimitedIndia | Vivilon Pharmaceuticals Inc.Importer: Medethix, Inc. | DRP-17289-01 | Nov 17, 2030 | |
ValsitrilSacubitril + Valsartan | 200 mg (eq. to 97.2 mg Sacubitril + 102.8 mg Valsartan sodium salt complex) Film-Coated tabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Bafna Pharmaceuticals LimitedIndia | Vivilon Pharmaceuticals Inc.Importer: Medethix, Inc. | DRP-17290-01 | Nov 17, 2030 | |
ValsorinSacubitril + Valsartan | 100 mg (eq. to Sacubitril 48.6 mg + Valsartan 51.4 mg) Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Hebei Tiancheng Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-18690 | Aug 25, 2031 | |
ValsorinSacubitril + Valsartan | 200 mg (eq. to Sacubitril 97.2 mg + Valsartan 102.8 mg) Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Hebei Tiancheng Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-18689 | Aug 25, 2031 | |
ValsorinSacubitril + Valsartan | 50 mg (eq. to Sacubitril 24.3 mg + Valsartan 25.7 mg) Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Hebei Tiancheng Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-18691 | Aug 25, 2031 | |
ValtrilSacubitril + Valsartan | 100 mg Film-Coated Tablet (eq. to Sacubitril 48.6 mg + Valsartan 51.4 mg sodium salt complex)Alu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Exemed PharmaceuticalsIndia | Pharma Hub CorporationImporter: Amb Hk Enterprises Inc. | DRP-16447-01 | Mar 18, 2030 | |
ValtrilSacubitril + Valsartan | 200 mg Film-Coated Tablet (eq. to Sacubitril 97.2 mg + Valsartan 102.8 mg sodium salt complex)Alu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Exemed PharmaceuticalsIndia | Pharma Hub CorporationImporter: Amb Hk Enterprises Inc. | DRP-16446-01 | Mar 18, 2030 | |
ValtrilSacubitril + Valsartan | 50 mg Film-Coated Tablet (eq. to Sacubitril 24.3 mg + Valsartan 25.7 mg sodium salt complex)Alu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Exemed PharmaceuticalsIndia | Pharma Hub CorporationImporter: Amb Hk Enterprises Inc. | DRP-16448-01 | Mar 18, 2030 | |
ValtrisSacubitril + Valsartan | 100 mg Film-Coated Tablet (eq. to 48.6 mg Sacubitril + 51.4 mg Valsartan) Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Baroque Pharmaceuticals Private LimitedIndia | AMB HK Enterprises Inc. | DRP-17453 | Dec 19, 2031 | |
ValtrisSacubitril + Valsartan | 200 mg Film-Coated Tablet (eq. to 97.2 mg Sacubitril + 102.8 mg Valsartan) Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Baroque Pharmaceuticals Private LimitedIndia | AMB HK Enterprises Inc. | DRP-17452 | Dec 19, 2031 | |
ValtrisSacubitril + Valsartan | 50 mg Film-Coated Tablet (eq. to 24.3 mg Sacubitril + 25.7 mg Valsartan Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Baroque Pharmaceuticals Private LimitedIndia | AMB HK Enterprises Inc. | DRP-17454 | Dec 19, 2031 | |
ValuzSacubitril + Valsartan | 100 mg Film-Coated Tablet (eq. to Sacubitril 48.6 mg + Valsartan 51.4 mg sodium salt complex)Alu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Exemed PharmaceuticalsIndia | The Cathay YSS Distributors Co., Inc.Importer: AMB HK Enterprises Inc. | DRP-16447-04 | Mar 18, 2030 | |
ValuzSacubitril + Valsartan | 200 mg (eq. to Sacubitril 97.2 mg + Valsartan 102.8 mg sodium salt complex) Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Exemed PharmaceuticalsIndia | The Cathay YSS Distributors Co., Inc.Importer: AMB HK Enterprises Inc. | DRP-16446-03 | Mar 18, 2030 | |
Vasacad-S 24/26Sacubitril + Valsartan | 50 mg to (eq Sacubitril 24 mg + Valsartan 26 mg in sodium salt complex) Film-Coated TabletAlu/Alu blister pack x 10's (box of 30's) | Rx | Hetero Labs Limited (Unit III)India | Camber Pharmaceuticals, Inc | DR-XY49275 | Nov 14, 2029 | |
Vasacad-S 49/51Sacubitril + Valsartan | 100 mg (eq. to Sacubitril 49 mg + Valsartan 51 mg in sodium salt complex) Film-Coated TabletAlu/Alu blister pack x 10's (box of 30's) | Rx | Hetero Labs Limited (Unit III)India | Camber Pharmaceuticals, Inc. | DR-XY49274 | Nov 14, 2029 | |
Vasacad-S 97/103Sacubitril + Valsartan | 200 mg (eq. to Sacubitril 97 mg + Valsartan 103 mg in sodium salt complex Film-Coated TabletAlu/Alu blister pack x 10's (box of 30's) | Rx | Hetero Labs Limited (Unit III)India | Camber Pharmaceuticals, Inc. | DR-XY49272 | Nov 13, 2029 | |
VictorisSacubitril + Valsartan | 100 mg (equivalent to Sacubitril 49 mg + Valsartan 51 mg) Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | BDR Pharmaceuticals International Private LimitedIndia | Unilab, Inc. | DRP-18624 | Aug 11, 2031 | |
VictorisSacubitril + Valsartan | 200 mg (equivalent to Sacubitril 97 mg + Valsartan 103 mg) Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | BDR Pharmaceuticals International Private LimitedIndia | Unilab, Inc. | DRP-18623 | Aug 11, 2031 | |
VictorisSacubitril + Valsartan | 50 mg (equivalent to Sacubitril 24 mg + Valsartan 26 mg) Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | BDR Pharmaceuticals International Private LimitedIndia | Unilab, Inc. | DRP-18625 | Aug 11, 2031 | |
ViltranSacubitril + Valsartan | 100 mg (eq. to Sacubitril 48.6 mg + Valsartan 51.4 mg sodium salt complex) Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Exemed PharmaceuticalsIndia | Pro Medica Inc.Importer: AMB HK Enterprises Inc. | DRP-16447-06 | Mar 18, 2030 | |
ViltranSacubitril + Valsartan | 200 mg Film-Coated Tablet (eq. to Sacubitril 97.2 mg + Valsartan 102.8 mg sodium salt complex)Alu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Exemed PharmaceuticalsIndia | Pro Medica Inc.Importer: AMB HK Enterprises Inc. | DRP-16446-06 | Mar 18, 2030 | |
ViltranSacubitril + Valsartan | 50 mg Film-Coated Tablet (eq. to Sacubitril 24.3 mg + Valsartan 25.7 mg sodium salt complex)Alu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Exemed PharmaceuticalsIndia | Pro Medica Inc.Importer: AMB HK Enterprises Inc. | DRP-16448-04 | Mar 18, 2030 | |
VytrilSacubitril + Valsartan | 100 mg Film-Coated Tablet (eq. to Sacubitril 48.6 mg + Valsartan 51.4 mg sodium salt complex)Alu/Alu Blister Pack x 10's (Box of 30's) | Rx | Avantika Medex Private LimitedIndia | One Technodrug Life Sciences Inc.Importer: Nelpa Lifesciences, Inc. | DRP-17568-02 | Jan 27, 2031 | |
VytrilSacubitril + Valsartan | 200 mg Film-Coated Tablet (eq. to Sacubitril 97.2 mg + Valsartan 102.8 mg sodium salt complex)Alu/Alu Blister Pack x 10's (Box of 30's) | Rx | Avantika Medex Private LimitedIndia | One Technodrug Life Sciences Inc.Importer: Nelpa Lifesciences, Inc. | DRP-17567-04 | Jan 27, 2031 | |
ZACUVIONSacubitril + Valsartan | 100 mg (equivalent to 48.6 mg Sacubitril and 51.4 mg Valsartan sodium salt complex) Film-coated TabletAlu/Alu Blister Packs x 10's (Box of 30's) | Rx | Bafna Pharmaceuticals LimitedIndia | TGP Pharma Inc.Importer: Medethix, Inc. | DRP-17289-04 | Nov 17, 2030 | |
ZacuvionSacubitril + Valsartan | 200 mg (eq. to 97.2 mg Sacubitril + 102.8 mg Valsartan sodium salt complex) Film-coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Bafna Pharmaceuticals Limited,India | TGP Pharma Inc.Importer: Medethix, Inc. | DRP-17290-04 | Nov 17, 2030 | |
ZacuvionSacubitril + Valsartan | 50 mg (equivalent to 24 mg Sacubitril + 26 mg Valsartan sodium salt complex) Film-coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Bafna Pharmaceuticals LimitedIndia | TGP Pharma Inc.Importer: Medethix, Inc. | DRP-17288-04 | Nov 17, 2030 | |
Zaref 100Sacubitril + Valsartan | 100 mg(eq. to 48.6 mg sacubitril + 51.4 mg valsartan sodium salt complex) Film-Coated TabletAlu/Alu blister pack x 14’s (Box of 28’s) Alu/Alu blister pack x 10’s (Box of 30’s) | Rx | Next Wave (India)India | Zydus Healthcare Philippines, Inc.Trader: N/A | DR-XY49646 | Feb 18, 2031 | |
Zaref 200Sacubitril + Valsartan | 200 mg (eq. to 97.2 mg sacubitril + 102.8 mg valsartan sodium salt complex) Film-Coated TabletAlu/Alu blister pack x 7's (box of 28's) Alu/Alu blister pack x 10's (box of 30's) | Rx | Next Wave (India)India | Zydus Healthcare Philippines, Inc.Trader: N/A | DR-XY49645 | Feb 18, 2031 | |
Zaref 200Sacubitril + Valsartan | 200 mg Film-Coated Tablet (eq. to 97.2 mg Sacubitril + 102.8 mg Valsartan)Alu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Exemed PharmaceuticalsIndia | Zydus Healthcare Philippines Inc.Importer: AMB HK Enterprises Inc. | DRP-16446-09 | Mar 18, 2030 | |
Zaref 50Sacubitril + Valsartan | 50 mg (eq. to Sacubitril 24.3 mg + Valsartan 25.7 mg sodium salt complex) Film-Coated Tablet | Rx | Next Wave (IndiaIndia | Zydus Healthcare Philippines, Inc. | DR-XY49647 | Feb 18, 2031 | |
Zaref 50Sacubitril + Valsartan | 50 mg Film-Coated Tablet (eq. to 24.3 mg Sacubitril + 25.7 mg Valsartan)Alu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Exemed PharmaceuticalsIndia | Zydus Healthcare Philippines Inc.Importer: AMB HK Enterprises Inc. | DRP-16448-10 | Mar 18, 2030 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS ENTRESTO film-coated tablets are supplied as unscored, ovaloid tablets in the following strengths: ENTRESTO 24/26 mg, (sacubitril 24 mg and valsartan 26 mg) are violet white and debossed with “NVR” on one side and “LZ” on the other side. ENTRESTO 49/51 mg, (sacubitril 49 mg and valsartan 51 mg) are pale yellow and debossed with “NVR” on one side and “L1” on the other side.
ENTRESTO 97/103 mg, (sacubitril 97 mg and valsartan 103 mg) are light pink and debossed with “NVR” on one side and “L11” on the other side. ENTRESTO SPRINKLE film-coated oral pellets are contained in a hard capsule in the following strengths: ENTRESTO SPRINKLE 6/6 mg, (sacubitril 6 mg and valsartan 6 mg) consists of a white colored cap with “04” and a transparent body with “NVR” and both parts with arrows.
ENTRESTO SPRINKLE 15/16 mg, (sacubitril 15 mg and valsartan 16 mg) consists of a yellow colored cap with “10” and a transparent body with “NVR” and both parts with arrows. Film-coated tablets: 24/26 mg; 49/51 mg; 97/103 mg (3) Film-coated oral pellets within capsules: 6 mg/6 mg; 15 mg/16 mg (3)
Warnings/Precautions
The boxed warning is shown at the top of this page.
- Observe for signs and symptoms of angioedema and hypotension. (5.2, 5.3)
- Monitor renal function and potassium in susceptible patients. (5.4, 5.5)
5.1 Fetal Toxicity
5.1 Fetal Toxicity ENTRESTO can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. When pregnancy is detected, consider alternative drug treatment and discontinue ENTRESTO.
However, if there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system, and if the drug is considered lifesaving for the mother, advise a pregnant woman of the potential risk to the fetus [see Use in Specific Populations (8.1)].
5.2 Angioedema
5.2 Angioedema ENTRESTO may cause angioedema [see Adverse Reactions (6.1)]. If angioedema occurs, discontinue ENTRESTO immediately, provide appropriate therapy, and monitor for airway compromise. ENTRESTO must not be re-administered. In cases of confirmed angioedema where swelling has been confined to the face and lips, the condition has generally resolved without treatment, although antihistamines have been useful in relieving symptoms.
Angioedema associated with laryngeal edema may be fatal. Where there is involvement of the tongue, glottis or larynx, likely to cause airway obstruction, administer appropriate therapy, e.g., subcutaneous epinephrine/adrenaline solution 1:1000 (0.3 mL to 0.5 mL) and take measures necessary to ensure maintenance of a patent airway.
ENTRESTO has been associated with a higher rate of angioedema in Black than in non-Black patients. Patients with a prior history of angioedema may be at increased risk of angioedema with ENTRESTO [see Adverse Reactions (6.1)]. ENTRESTO must not be used in patients with a known history of angioedema related to previous ACE inhibitor or ARB therapy [see Contraindications (4)].
ENTRESTO should not be used in patients with hereditary angioedema.
5.3 Hypotension
5.3 Hypotension ENTRESTO lowers blood pressure and may cause symptomatic hypotension [see Adverse Reactions (6.1)]. Patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics), are at greater risk. Correct volume or salt depletion prior to administration of ENTRESTO or start at a lower dose.
If hypotension occurs, consider dose adjustment of diuretics, concomitant antihypertensive drugs, and treatment of other causes of hypotension (e.g., hypovolemia). If hypotension persists despite such measures, reduce the dosage or temporarily discontinue ENTRESTO. Permanent discontinuation of therapy is usually not required.
5.4 Impaired Renal Function
5.4 Impaired Renal Function As a consequence of inhibiting the renin-angiotensin-aldosterone system (RAAS), decreases in renal function may be anticipated in susceptible individuals treated with ENTRESTO [see Adverse Reactions (6.1)]. In patients whose renal function depends upon the activity of the renin-angiotensin-aldosterone system (e.g., patients with severe congestive heart failure), treatment with ACE inhibitors and angiotensin receptor antagonists has been associated with oliguria, progressive azotemia and, rarely, acute renal failure and death.
Closely monitor serum creatinine, and down-titrate or interrupt ENTRESTO in patients who develop a clinically significant decrease in renal function [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)]. As with all drugs that affect the RAAS, ENTRESTO may increase blood urea and serum creatinine levels in patients with bilateral or unilateral renal artery stenosis.
In patients with renal artery stenosis, monitor renal function.
5.5 Hyperkalemia
5.5 Hyperkalemia Through its actions on the RAAS, hyperkalemia may occur with ENTRESTO [see Adverse Reactions (6.1)]. Monitor serum potassium periodically and treat appropriately, especially in patients with risk factors for hyperkalemia such as severe renal impairment, diabetes, hypoaldosteronism, or a high potassium diet.
Dosage reduction or interruption of ENTRESTO may be required [see Dosage and Administration (2.7)].
Drug interactions
- Avoid concomitant use with aliskiren in patients with estimated glomerular filtration rate (eGFR) less than 60. (7.1)
- Potassium-sparing diuretics: May lead to increased serum potassium. (7.2)
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): May lead to increased risk of renal impairment. (7.3)
- Lithium: Increased risk of lithium toxicity. (7.4)
7.1 Dual Blockade of the Renin-Angiotensin-Aldosterone System
7.1 Dual Blockade of the Renin-Angiotensin-Aldosterone System Concomitant use of ENTRESTO with an ACE inhibitor is contraindicated because of the increased risk of angioedema [see Contraindications (4)]. Avoid use of ENTRESTO with an ARB, because ENTRESTO contains the angiotensin II receptor blocker valsartan. The concomitant use of ENTRESTO with aliskiren is contraindicated in patients with diabetes [see Contraindications (4)].
Avoid use with aliskiren in patients with renal impairment (eGFR less than 60 mL/min/1.73 m²).
7.2 Potassium-Sparing Diuretics
7.2 Potassium-Sparing Diuretics As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium [see Warnings and Precautions (5.5)].
7.3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Including Selective Cyclooxygenase-2…
7.3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, concomitant use of NSAIDs, including COX-2 inhibitors, with ENTRESTO may result in worsening of renal function, including possible acute renal failure. These effects are usually reversible.
Monitor renal function periodically.
7.4 Lithium
7.4 Lithium Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists. Monitor serum lithium levels during concomitant use with ENTRESTO.
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
Drug Interactions: Effect of Co-administered Drugs on ENTRESTO: Because CYP450 enzyme-mediated metabolism of sacubitril and valsartan is minimal, coadministration with drugs that impact CYP450 enzymes is not expected to affect the pharmacokinetics of ENTRESTO.
Effect of ENTRESTO on Co-administered Drugs: In vitro data indicate that sacubitril inhibits OATP1B1 and OATP1B3 transporters.
Adverse reactions
- Clinically significant adverse reactions that appear in other sections of the labeling include: Angioedema [see Warnings and Precautions (5.2)] Hypotension [see Warnings and Precautions (5.3)] Impaired Renal Function [see Warnings and Precautions (5.4)] Hyperkalemia [see Warnings and Precautions (5.5)] Adverse reactions occurring greater than or equal to 5% are hypotension, hyperkalemia, cough, dizziness, and renal failure. (6.1)
- To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. A total of 6,622 heart failure patients were treated with ENTRESTO in the PARADIGM-HF (vs. enalapril) and PARAGON-HF (vs. valsartan) clinical trials.
Of these, 5,085 were exposed for at least 1 year. Adult Heart Failure In PARADIGM-HF, patients were required to complete sequential enalapril and ENTRESTO run-in periods of (median) 15 and 29 days, respectively, prior to entering the randomized double-blind period comparing ENTRESTO and enalapril. During the enalapril run-in period, 1,102 patients (10.5%) were permanently discontinued from the study, 5.6% because of an adverse event, most commonly renal dysfunction (1.7%), hyperkalemia (1.7%) and hypotension (1.4%).
During the ENTRESTO run-in period, an additional 10.4% of patients permanently discontinued treatment, 5.9% because of an adverse event, most commonly renal dysfunction (1.8%), hypotension (1.7%) and hyperkalemia (1.3%). Because of this run-in design, the adverse reaction rates described below are lower than expected in practice.
In the double-blind period, safety was evaluated in 4,203 patients treated with ENTRESTO and 4,229 treated with enalapril. In PARADIGM-HF, patients randomized to ENTRESTO received treatment for up to 4.3 years, with a median duration of exposure of 24 months; 3,271 patients were treated for more than one year. Discontinuation of therapy because of an adverse event during the double-blind period occurred in 450 (10.7%) of ENTRESTO-treated patients and 516 (12.2%) of patients receiving enalapril.
Adverse reactions occurring at an incidence of greater than or equal to 5% in patients who were treated with ENTRESTO in the double-blind period of PARADIGM-HF are shown in Table 3. In PARADIGM-HF, the incidence of angioedema was 0.1% in both the enalapril and ENTRESTO run-in periods. In the double-blind period, the incidence of angioedema was higher in patients treated with ENTRESTO than enalapril (0.5% and 0.2%, respectively).
The incidence of angioedema in Black patients was 2.4% with ENTRESTO and 0.5% with enalapril [see Warnings and Precautions (5.2)]. Orthostasis was reported in 2.1% of patients treated with ENTRESTO compared to 1.1% of patients treated with enalapril during the double-blind period of PARADIGM-HF. Falls were reported in 1.9% of patients treated with ENTRESTO compared to 1.3% of patients treated with enalapril.
Table 3: Adverse Reactions Reported in greater than or equal to 5% of Patients Treated with ENTRESTO in the Double-Blind Period of PARADIGM-HF ENTRESTO (n = 4,203) % Enalapril (n = 4,229) % Hypotension 18 12 Hyperkalemia 12 14 Cough 9 13 Dizziness 6 5 Renal failure/acute renal failure 5 5 In PARAGON-HF, no new adverse reactions were identified. Pediatric Heart Failure The adverse reactions observed in pediatric patients 1 year to less than 18 years old who received treatment with ENTRESTO were consistent with those observed in adult patients.
Laboratory Abnormalities Hemoglobin and Hematocrit Decreases in hemoglobin/hematocrit of greater than 20% were observed in approximately 5% of both ENTRESTO- and enalapril-treated patients in the double-blind period in PARADIGM-HF. Decreases in hemoglobin/hematocrit of greater than 20% were observed in approximately 7% of ENTRESTO-treated patients and 9% of valsartan-treated patients in the double-blind period in PARAGON-HF.
Serum Creatinine During the double-blind period in PARADIGM-HF, approximately 16% of both ENTRESTO- and enalapril-treated patients had increases in serum creatinine of greater than 50%. During the double-blind period in PARAGON-HF, approximately 17% of ENTRESTO-treated patients and 21% of valsartan-treated patients had increases in serum creatinine of greater than 50%.
Serum Potassium During the double-blind period of PARADIGM-HF, approximately 16% of both ENTRESTO- and enalapril-treated patients had potassium concentrations greater than 5.5 mEq/L. During the double-blind period of PARAGON-HF, approximately 18% of ENTRESTO-treated patients and 20% of valsartan-treated patients had potassium concentrations greater than 5.5 mEq/L.
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following additional adverse reactions have been reported in postmarketing experience. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Hypersensitivity including rash, pruritus, and anaphylactic reaction
Adverse reaction frequency tables (US label) US FDA label
| ENTRESTO (n = 4,203) % | Enalapril (n = 4,229) % | |
| Hypotension | 18 | 12 |
| Hyperkalemia | 12 | 14 |
| Cough | 9 | 13 |
| Dizziness | 6 | 5 |
| Renal failure/acute renal failure | 5 | 5 |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary ENTRESTO can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death (see Clinical Considerations). Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents.
In animal reproduction studies, ENTRESTO treatment during organogenesis resulted in increased embryo-fetal lethality in rats and rabbits and teratogenicity in rabbits (see Data). When pregnancy is detected, consider alternative drug treatment and discontinue ENTRESTO. However, if there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system, and if the drug is considered lifesaving for the mother, advise a pregnant woman of the potential risk to the fetus.
The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Clinical Considerations Fetal/Neonatal Adverse Reactions Oligohydramnios in pregnant women who use drugs affecting the renin-angiotensin system in the second and third trimesters of pregnancy can result in the following: reduced fetal renal function leading to anuria and renal failure, fetal lung hypoplasia, skeletal deformations, including skull hypoplasia, hypotension, and death. Perform serial ultrasound examinations to assess the intra-amniotic environment.
Fetal testing may be appropriate, based on the week of gestation. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. If oligohydramnios is observed, consider alternative drug treatment. Closely observe neonates with histories of in utero exposure to ENTRESTO for hypotension, oliguria, and hyperkalemia.
In neonates with a history of in utero exposure to ENTRESTO, if oliguria or hypotension occurs, support blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and replacing renal function. Data Animal Data ENTRESTO treatment during organogenesis resulted in increased embryo-fetal lethality in rats at doses greater than or equal to 49 mg sacubitril/51 mg valsartan/kg/day (less than or equal to 0.06 [LBQ657, the active metabolite] and 0.72 [valsartan]-fold the maximum recommended human dose [MRHD] of 97/103 mg twice-daily on the basis of the area under the plasma drug concentration-time curve [AUC]) and rabbits at doses greater than or equal to 5 mg sacubitril/5 mg valsartan/kg/day (2-fold and 0.03-fold the MRHD on the basis of valsartan and LBQ657 AUC, respectively).
ENTRESTO is teratogenic based on a low incidence of fetal hydrocephaly, associated with maternally toxic doses, which was observed in rabbits at an ENTRESTO dose of greater than or equal to 5 mg sacubitril/5 mg valsartan/kg/day. The adverse embryo-fetal effects of ENTRESTO are attributed to the angiotensin receptor antagonist activity.
Pre- and postnatal development studies in rats at sacubitril doses up to 750 mg/kg/day (2.2-fold the MRHD on the basis of LBQ657 AUC) and valsartan at doses up to 600 mg/kg/day (0.86-fold the MRHD on the basis of AUC) indicate that treatment with ENTRESTO during organogenesis, gestation and lactation may affect pup development and survival.
Mechanism of action
12.1 Mechanism of Action ENTRESTO contains a neprilysin inhibitor, sacubitril, and an angiotensin receptor blocker, valsartan. ENTRESTO inhibits neprilysin (neutral endopeptidase; NEP) via LBQ657, the active metabolite of the prodrug sacubitril, and blocks the angiotensin II type-1 (AT 1) receptor via valsartan. The cardiovascular and renal effects of ENTRESTO in heart failure patients are attributed to the increased levels of peptides that are degraded by neprilysin, such as natriuretic peptides, by LBQ657, and the simultaneous inhibition of the effects of angiotensin II by valsartan.
Valsartan inhibits the effects of angiotensin II by selectively blocking the AT 1 receptor, and also inhibits angiotensin II-dependent aldosterone release.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics The pharmacodynamic effects of ENTRESTO were evaluated after single and multiple dose administrations in healthy subjects and in patients with heart failure, and are consistent with simultaneous neprilysin inhibition and renin-angiotensin system blockade. In a 7-day valsartan-controlled study in patients with reduced ejection fraction (HFrEF), administration of ENTRESTO resulted in a significant non-sustained increase in natriuresis, increased urine cGMP, and decreased plasma MR-proANP and NT-proBNP compared to valsartan.
In a 21-day study in HFrEF patients, ENTRESTO significantly increased urine ANP and cGMP and plasma cGMP, and decreased plasma NT-proBNP, aldosterone and endothelin-1. ENTRESTO also blocked the AT 1 -receptor as evidenced by increased plasma renin activity and plasma renin concentrations. In PARADIGM-HF, ENTRESTO decreased plasma NT-proBNP (not a neprilysin substrate) and increased plasma BNP (a neprilysin substrate) and urine cGMP compared with enalapril.
In PARAMOUNT, a randomized, double-blind, 36-week study in patients with heart failure with LVEF greater than or equal to 45% comparing 97/103 mg of ENTRESTO (n=149) to 160 mg of valsartan (n =152) twice-daily, ENTRESTO decreased NT-proBNP by 17% while valsartan increased NT-proBNP by 8% at Week 12 (p = 0.005). In PARAGON-HF, ENTRESTO decreased NT-proBNP by 24% (Week 16) and 19% (Week 48) compared to 6% and 3% reductions on valsartan, respectively.
In PANORAMA-HF, a reduction in NT-proBNP was observed at Weeks 4 and 12 for ENTRESTO (40% and 50%) compared to baseline. The NT-proBNP levels continued to decrease over the duration of the study with a reduction of 65% for ENTRESTO at Week 52 compared to baseline. QT Prolongation: In a thorough QTc clinical study in healthy male subjects, single doses of ENTRESTO 194 mg sacubitril/206 mg valsartan and 583 mg sacubitril/617 mg valsartan had no effect on cardiac repolarization.
Amyloid-β: Neprilysin is one of multiple enzymes involved in the clearance of amyloid-β (Aβ) from the brain and cerebrospinal fluid (CSF). Administration of ENTRESTO 194 mg sacubitril/206 mg valsartan once-daily for 2 weeks to healthy subjects was associated with an increase in CSF Aβ 1-38 compared to placebo; there were no changes in concentrations of CSF Aβ 1-40 or CSF Aβ 1-42.
The clinical relevance of this finding is unknown [see Nonclinical Toxicology (13)]. Blood Pressure: Addition of a 50 mg single dose of sildenafil to ENTRESTO at steady state (194 mg sacubitril/206 mg valsartan once daily for 5 days) in patients with hypertension was associated with additional blood pressure (BP) reduction (approximately 5/4 mmHg, systolic/diastolic BP) compared to administration of ENTRESTO alone.
Co-administration of ENTRESTO did not significantly alter the BP effect of intravenous nitroglycerin.
Pharmacokinetics
Elimination Following oral administration, 52% to 68% of sacubitril (primarily as LBQ657) and approximately 13% of valsartan and its metabolites are excreted in urine; 37% to 48% of sacubitril (primarily as LBQ657), and 86% of valsartan and its metabolites are excreted in feces.
Sacubitril, LBQ657, and valsartan are eliminated from plasma with a mean elimination half-life (T 1/2 ) of approximately 1.4 hours, 11.5 hours, and 9.9 hours, respectively.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Absorption Following oral administration, ENTRESTO dissociates into sacubitril and valsartan. Sacubitril is further metabolized to LBQ657. The peak plasma concentrations of sacubitril, LBQ657, and valsartan are reached in 0.5 hours, 2 hours, and 1.5 hours, respectively. The oral absolute bioavailability of sacubitril is estimated to be greater than or equal to 60%.
The valsartan in ENTRESTO is more bioavailable than the valsartan in other marketed tablet formulations; 26 mg, 51 mg, and 103 mg of valsartan in ENTRESTO is equivalent to 40 mg, 80 mg, and 160 mg of valsartan in other marketed tablet formulations, respectively. Following twice-daily dosing of ENTRESTO, steady-state levels of sacubitril, LBQ657, and valsartan are reached in 3 days.
At steady state, sacubitril and valsartan do not accumulate significantly, whereas LBQ657 accumulates by 1.6-fold. ENTRESTO administration with food has no clinically significant effect on the systemic exposures of sacubitril, LBQ657, or valsartan. Although there is a decrease in exposure to valsartan when ENTRESTO is administered with food, this decrease is not accompanied by a clinically significant reduction in the therapeutic effect.
ENTRESTO can therefore be administered with or without food. Distribution Sacubitril, LBQ657 and valsartan are highly bound to plasma proteins (94% to 97%). Based on the comparison of plasma and CSF exposures, LBQ657 crosses the blood brain barrier to a limited extent (0.28%). The average apparent volumes of distribution of valsartan and sacubitril are 75 and 103 L, respectively.
Metabolism Sacubitril is readily converted to LBQ657 by esterases; LBQ657 is not further metabolized to a significant extent. Valsartan is minimally metabolized; only about 20% of the dose is recovered as metabolites. A hydroxyl metabolite has been identified in plasma at low concentrations (less than 10%). Elimination Following oral administration, 52% to 68% of sacubitril (primarily as LBQ657) and approximately 13% of valsartan and its metabolites are excreted in urine; 37% to 48% of sacubitril (primarily as LBQ657), and 86% of valsartan and its metabolites are excreted in feces.
Sacubitril, LBQ657, and valsartan are eliminated from plasma with a mean elimination half-life (T 1/2) of approximately 1.4 hours, 11.5 hours, and 9.9 hours, respectively. Linearity/Nonlinearity The pharmacokinetics of sacubitril, LBQ657, and valsartan were linear over an ENTRESTO dose range of 24 mg sacubitril/26 mg valsartan to 194 mg sacubitril/206 mg valsartan.
Drug Interactions: Effect of Co-administered Drugs on ENTRESTO: Because CYP450 enzyme-mediated metabolism of sacubitril and valsartan is minimal, coadministration with drugs that impact CYP450 enzymes is not expected to affect the pharmacokinetics of ENTRESTO. Dedicated drug interaction studies demonstrated that coadministration of furosemide, warfarin, digoxin, carvedilol, a combination of levonorgestrel/ethinyl estradiol, amlodipine, omeprazole, hydrochlorothiazide (HCTZ), metformin, atorvastatin, and sildenafil, did not alter the systemic exposure to sacubitril, LBQ657 or valsartan.
Effect of ENTRESTO on Co-administered Drugs: In vitro data indicate that sacubitril inhibits OATP1B1 and OATP1B3 transporters. The effects of ENTRESTO on the pharmacokinetics of coadministered drugs are summarized in Figure 1. Figure 1: Effect of ENTRESTO on Pharmacokinetics of Coadministered Drugs Specific Populations Effect of specific populations on the pharmacokinetics of LBQ657 and valsartan are shown in Figure 2.
Figure 2: Pharmacokinetics of ENTRESTO in Specific Populations Note: Child-Pugh Classification was used for hepatic impairment. Pediatric Patients: The pharmacokinetics of ENTRESTO were evaluated in pediatric heart failure patients 1 to less than 18 years old administered oral doses of 0.8 mg/kg and 3.1 mg/kg of ENTRESTO.
Pharmacokinetic data indicated that exposure to ENTRESTO in pediatric and adult patients is similar. Figure 1: Effect of ENTRESTO on Pharmacokinetics of Coadministered Drugs Figure 2: Pharmacokinetics of ENTRESTO in Specific Populations
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Sacubitril/Valsartan 50 mg Tablet | ₱55.25–₱56.25Reference ₱55.25 | per tablet | DPRI procurement range |
| Sacubitril/Valsartan 100 mg Tablet | ₱56.25Reference ₱56.25 | per tablet | DPRI procurement range |
| Sacubitril/Valsartan 200 mg Tablet | ₱56.25Reference ₱56.25 | per tablet | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Sacubitril/Valsartan |
| PNF listing | Oral: 50 mg, 100 mg and 200 mg tablet (Restricted for patients with symptomatic heart failure with reduced injection fraction (HF-rEF) and for those who have been on stable doses of angiotensin- converting enzyme (ACE) inhibitors and/or angiotensin receptor blockers (ARBs) but remain symptomatic.)Restrictions: Restricted for patients with symptomatic heart failure with reduced injection fraction (HF-rEF) and for those who have been on stable doses of angiotensin- converting enzyme (ACE) inhibitors and/or angiotensin receptor blockers (ARBs) but remain symptomatic |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. ENTRESTO · Novartis Pharmaceuticals Corporation [US FDA-approved label, version 25, July 6, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=000dc81d-ab91-450c-8eae-8eb74e72296f
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .

